Form 4: KALA BIO Executive Sells Shares for Tax Obligations Under Pre-Arranged Plan

KALA BIO, Inc.'s Interim CEO, President, and COO, Todd Bazemore, sold 4,058 shares of common stock for tax withholding purposes related to RSU vesting.

Summary

• Todd Bazemore, Interim Chief Executive Officer, President, and Chief Operating Officer of KALA BIO, Inc. (KALA), sold 4,058 shares of the company's common stock.
• The transaction occurred on June 24, 2025, at a weighted average price of $4.01 per share, with individual sales ranging from $3.87 to $4.12.
• The sale was executed under a pre-arranged 10b5-1 trading plan, which was adopted on November 10, 2020.
• The stated purpose of the sale was to cover tax withholding obligations associated with the vesting and settlement of restricted stock units (RSUs) granted to Mr. Bazemore on June 22, 2023.
• Following this transaction, Mr. Bazemore beneficially owns 83,699 shares of KALA BIO common stock, which includes 35,732 unvested RSUs.
• Additionally, Mr. Bazemore indirectly owns 1 share through his son.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the explicit reason for the sale (tax withholding via a 10b5-1 plan) mitigates concerns about a lack of confidence in the company. It's a routine transaction for executives.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new information.
• The sale was explicitly for tax withholding obligations, which is a common and often non-discretionary reason for insider sales, mitigating concerns about a lack of confidence.

Negatives

• An insider sale, even for tax purposes, reduces the executive's direct equity stake in the company.
• The sale occurred at a weighted average price of $4.01, which could be perceived negatively if the stock price is significantly higher or lower than recent trading ranges.

Risks

• Potential for negative market perception if investors misinterpret the sale as a lack of confidence, despite the stated tax-related reason.
• Fluctuations in stock price could impact the value of the remaining unvested RSUs and directly held shares.

Future Outlook

N/A

Management Comments

• "This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 10, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ('RSUs') granted on June 22, 2023."
• "The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction for tax purposes and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology sector. Such transactions are common for executives receiving equity compensation.

Comparison to Industry Standards

• N/A. This document reports an individual insider transaction for tax purposes, which is not typically compared to industry-wide performance benchmarks or specific company projects.

Management Changes

Corporate Governance

Legal Proceedings

• N/A. The document does not mention any litigation or regulatory matters.

Related Party Transactions

• The sale of common stock by Todd Bazemore, an officer of KALA BIO, Inc., constitutes a related party transaction as it involves an executive and the company's securities.

Stakeholder Impact

• Shareholders: May perceive the sale as a routine tax-related transaction, or potentially as a minor reduction in insider alignment, depending on their interpretation. The impact on share price is likely minimal given the stated reason and the relatively small number of shares compared to total outstanding shares.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• N/A. The document reports a completed transaction and does not outline future actions or milestones for the company.

Key Dates

Keywords

KALA BIO, KALA, Todd Bazemore, SEC Form 4, insider trading, stock sale, 10b5-1 plan, restricted stock units, RSU, tax withholding, executive compensation